Comparison of all pairs of individual markers in terms of their standardized association with COVID-19 risk
After an immune marker is accepted as a CoP for a certain vaccine, it typically will be used as a primary endpoint in an immunobridging study for comparing the geometric mean marker value between a new condition and a standard condition. Therefore, a criterion for comparing the quality of two accepted CoPs is the ratio of sample sizes required to power the future immunobridging study for comparing the geometric mean between the two randomized study arms. For all pairs of the five markers at each time point, Follmann’s method (